All In Biotech

Drug Trial Radar · NCT02899000

A Treatment for Severe Inflammatory Acne Subjects

Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects

Last checked: Nov 20, 2026Latest source record: Dec 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

186

Actual

Start

Jul 29, 2016

Primary completion

Mar 28, 2017

Study completion Jun 27, 2017

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Sep 13, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Demonstrate that a daily treatment regimen of adapalene 0.3%/benzoyl peroxide 2.5% gel + oral Doxycycline 200 mg is effective and safe in severe inflammatory acne with 3 or fewer nodules or cysts (non-nodulocystic) during a 12-week treatment period.

Conditions

  • Acne Vulgaris

Interventions

  • Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gelDrug

    Topical acne therapy

  • Oral doxycycline hyclateDrug

    Tetracycline-class oral antibacterial 200 mg daily (2 tablets \[50 mg\], twice daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Number of Inflammatory LesionsTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Galderma Laboratories, LP

    Fort Worth, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.